[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568241":3},{"organization":4,"armGroups":7,"interventions":39,"overallOfficials":16,"centralContacts":16,"locations":45,"responsibleParty":152,"collaborators":16,"id":154,"slug":155,"hasResults":156,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":156,"sex":162,"minAge":163,"maxAge":16,"enrollmentInfo":164,"targetDuration":16,"studyType":167,"phases":168,"briefSummary":171,"conditions":172,"keywords":177,"overallStatus":48,"whyStopped":16,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":190},{"fullName":5,"class":6},"Recursion Pharmaceuticals Inc.","INDUSTRY",[8,14,18,21,24,27,30,33,36],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 1a","EXPERIMENTAL","Dose Finding",[13],"Drug: REC-1245",{"label":15,"type":10,"description":16,"interventionNames":17},"Phase 1b Cohort A",null,[13],{"label":19,"type":10,"description":16,"interventionNames":20},"Phase 1b Cohort B",[13],{"label":22,"type":10,"description":16,"interventionNames":23},"Phase 1b Cohort C",[13],{"label":25,"type":10,"description":16,"interventionNames":26},"Phase 1b Cohort D",[13],{"label":28,"type":10,"description":16,"interventionNames":29},"Phase 2 Cohort 1 Dose #1",[13],{"label":31,"type":10,"description":16,"interventionNames":32},"Phase 2 Cohort 1 Dose #2",[13],{"label":34,"type":10,"description":16,"interventionNames":35},"Phase 2 Cohort 2 Dose #1",[13],{"label":37,"type":10,"description":16,"interventionNames":38},"Phase 2 Cohort 2 Dose #2",[13],[40],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":16},"DRUG","REC-1245","Oral",[9,15,19,22,25,28,31,34,37],[46,66,80,95,106,121,138],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"City of Hope","RECRUITING","Duarte","California","91010","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-117.97729,34.13945,{"lat":58,"lon":57},[61],{"name":62,"role":63,"phone":64,"phoneExt":16,"email":65},"Mihae Song","CONTACT","877-467-3411","misong@coh.org",{"facility":67,"status":48,"city":68,"state":50,"zip":69,"country":52,"countryCode":53,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Sarcoma Oncology Research Center","Santa Monica","90403",{"type":55,"coordinates":71},[72,73],-118.49138,34.01949,{"lat":73,"lon":72},[76],{"name":77,"role":63,"phone":78,"phoneExt":16,"email":79},"Victoria Chua","310-552-9999","chua@sarcomaonology.com",{"facility":81,"status":48,"city":82,"state":83,"zip":84,"country":52,"countryCode":53,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Cleveland Clinic","Cleveland","Ohio","44195",{"type":55,"coordinates":86},[87,88],-81.69541,41.4995,{"lat":88,"lon":87},[91],{"name":92,"role":63,"phone":93,"phoneExt":16,"email":94},"Jessica Grenbenc","216-444-7923","canceranswer@ccf.org",{"facility":96,"status":97,"city":98,"state":99,"zip":100,"country":52,"countryCode":53,"cosmosGeoPoint":101,"geoPoint":105,"contacts":16},"SCRI Oncology Partners - PPDS","WITHDRAWN","Nashville","Tennessee","37203",{"type":55,"coordinates":102},[103,104],-86.78444,36.16589,{"lat":104,"lon":103},{"facility":107,"status":48,"city":108,"state":109,"zip":110,"country":52,"countryCode":53,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"START Mountain Region","West Valley City","Utah","84119",{"type":55,"coordinates":112},[113,114],-112.00105,40.69161,{"lat":114,"lon":113},[117],{"name":118,"role":63,"phone":119,"phoneExt":16,"email":120},"Marie Asay","801-907-4750","marie.asay@startresearch.com",{"facility":122,"status":48,"city":123,"state":124,"zip":125,"country":126,"countryCode":127,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"Princess Margaret Cancer Centre","Toronto","Ontario","M5G 1X6","Canada","CA",{"type":55,"coordinates":129},[130,131],-79.39864,43.70643,{"lat":131,"lon":130},[134],{"name":135,"role":63,"phone":136,"phoneExt":16,"email":137},"Anh Nguyen","416-946-4501","anh.nguyen2@uhn.ca",{"facility":139,"status":48,"city":140,"state":16,"zip":141,"country":126,"countryCode":127,"cosmosGeoPoint":142,"geoPoint":146,"contacts":147},"McGill University Health Centre (MUHC) - The Montreal","Québec","H4A3J1",{"type":55,"coordinates":143},[144,145],-71.21454,46.81228,{"lat":145,"lon":144},[148],{"name":149,"role":63,"phone":150,"phoneExt":16,"email":151},"Phuong-nam Nguyen","5149341934","Phuong-nam.Nguyen@muhc.mcgill.ca",{"type":153,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR","100568241","phase-1-a-study-of-rec-1245-in-participants-with-unresectable-locally-advanced-or-metastatic-cancer-100568241",false,"NCT06678659","A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","A Phase 1 \u002F 2, Open-Label Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","DAHLIA","Inclusion Criteria:\n\n* Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed \u002F refractory lymphoma\n* Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy.\n* Eastern cooperative oncology group (ECOG) performance status ≤1; for adolescent participants, Lansky Performance Status Scale or Karnofsky Performance Status Scale score of ≥70.\n* Measurable disease at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 \u002F Lugano criteria and documented by computed tomography (CT) and \u002F or magnetic resonance imaging (MRI)\n\nExclusion Criteria:\n\n* Received treatment with another RBM39 degrader\n* Clinically significant gastrointestinal (GI) or GI malabsorption","ALL","12 Years",{"count":165,"type":166},170,"ESTIMATED","INTERVENTIONAL",[169,170],"PHASE1","PHASE2","This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.",[173,174,175,176],"Unresectable","Locally Advanced","Metastatic Cancers","Relapsed\u002FRefractory Lymphomas",[178,179,180,175],"RBM39","Cancer","Refractory Lymphomas","2026-08-18",{"date":183,"type":184},"2026-08-20","ACTUAL",{"date":186,"type":184},"2024-11-21",{"date":188,"type":166},"2028-10-30",{"name":5,"class":6},7]